Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07353931 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
A Phase 3 study of Osteoarthritis and Overweight or Obesity, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 900
- Enrollment target
- 20
- Study locations
NCT07353931: Recruiting Phase 3 study of Osteoarthritis and Overweight or Obesity, sponsored by Eli Lilly and Company.
NCT07353931 is a Phase 3 study of Osteoarthritis and Overweight or Obesity that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 900 participants, above the 811-participant average among 135 other Osteoarthritis trials with a reported enrollment target (11% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07353931, a Phase 3 study of Osteoarthritis and Overweight or Obesity, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 900 participants
- Enrollment target
- 20
- Study locations
Study Summary
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.
Primary Outcome
Percent Change from Baseline in Body Weight
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Eloralintide
Study Locations (20)
California
- Ark Clinical Research - Fountain Valley - Fountain Valley
- Wolverine Clinical Trials - Santa Ana
- Encompass Clinical Research - Spring Valley
- Diablo Clinical Research, Inc. - Walnut Creek
Arizona
- Care Access - 801 South Power Road, Mesa - Mesa
- Elite Pain and Spine Institute - South Crimson Road - Mesa
- Tucson Orthopaedic Institute - North Wyatt Drive - Tucson
Florida
- Westside Center for Clinical Research - Jacksonville
- Care Access - St. Petersburg - St. Petersburg
- Conquest Research - Winter Park
Massachusetts
- Skylight Health Research - Burlington - Burlington
- Care Access - Quincy - Quincy
New York
- Ellipsis Research Group - Brooklyn - 7th Street - Brooklyn
- Rochester Clinical Research - Buffalo - Buffalo
Alabama
- AMR Clinical - Mobile
Georgia
- Orita Clinical Research - Decatur
Illinois
- Great Lakes Clinical Trials - Ravenswood - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2026-02-09 |
| Est. Completion | 2028-05 |
| Phase | Phase 3 |
What NCT07353931 shows while recruiting
NCT07353931 is an interventional study that assigns participants to a tested intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, above the 811-participant average among 135 other Osteoarthritis trials with a reported enrollment target (11% higher).
The record links to 2 conditions, with Osteoarthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07353931 names 20 study sites across 11 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT07353931 about?
NCT07353931 is a clinical study titled "Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight". The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last abo...
What is the current status of trial NCT07353931?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 900 participants. The study started on 2026-02-09. Estimated completion is 2028-05.
What conditions does trial NCT07353931 study?
This clinical trial studies the following conditions: Osteoarthritis, Overweight or Obesity.
What interventions are being tested in trial NCT07353931?
The interventions under investigation include: Placebo (DRUG), Eloralintide (DRUG).
Who is sponsoring clinical trial NCT07353931?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07353931 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07353931's enrollment target sits among peer trials
900 15th of 135 higher than 120 of 135 other Osteoarthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoarthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Beat Pain Better Trial
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
RECRUITING · Phase 3
-
Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement
COMPLETED · Phase 3
-
Allograft Transplantation in the Treatment of Osteoarthritis of the Metatarsophalangeal (MTP) Joint of the Great Toe
COMPLETED · Phase 3
-
Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis
COMPLETED · Phase 3
-
Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial I
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
- NCT02960022 · 900 participants · Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI